WO1999007749A1 - Compose chimique complexe, synthese et applications diverses dudit compose - Google Patents
Compose chimique complexe, synthese et applications diverses dudit compose Download PDFInfo
- Publication number
- WO1999007749A1 WO1999007749A1 PCT/FR1998/001731 FR9801731W WO9907749A1 WO 1999007749 A1 WO1999007749 A1 WO 1999007749A1 FR 9801731 W FR9801731 W FR 9801731W WO 9907749 A1 WO9907749 A1 WO 9907749A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- organic polymer
- biomonomers
- solid support
- chemical compound
- biopolymers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
- C40B50/14—Solid phase synthesis, i.e. wherein one or more library building blocks are bound to a solid support during library creation; Particular methods of cleavage from the solid support
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F8/00—Chemical modification by after-treatment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/11—Compounds covalently bound to a solid support
Definitions
- the subject of the present invention is a complex chemical compound, its method of synthesis and its use for the synthesis of biopolymers. It also relates to the use of reagents obtained for, among other things, the amplification of detection and / or capture of different biological targets.
- ligands for example proteins, haptens, peptides, polypeptides, antibodies or polynucleotides to capture target molecules or anti-ligands (biological molecules or analogs), for the purpose of detecting and / or to measure them, especially in carrying out diagnostic tests.
- FR2 707 010 which discloses reagents and a device for capturing a target molecule of the sandwich type, comprising a solid support on which a ligand is adsorbed, said ligand consisting of a conjugate resulting from the covalent coupling of an organic polymer with a plurality of biopolymers, said organic polymer being a copolymer of N-vinyl-pyrrolidone.
- Patent application EP 561 722 discloses a water-soluble compound derived from a homopolymer or copolymer of maleic anhydride, which can be directly used to immobilize a biological molecule, without a prior activation step being necessary.
- the water-soluble compounds are derivatives of copolymers of maleic anhydride, and are used to immobilize at minus one biological molecule, to which it is linked directly or indirectly.
- Said biological molecule being chosen in particular from proteins such as antibodies or fragments of antibodies or antigens; polypeptides; enzymes; small molecules such as haptens; fragments of nucleic acids.
- Patent application WO 84/03053 discloses a solid support of polysaccharide type to which is covalently linked a synthetic polymer obtained by polymerization of comonomers to which is optionally covalently attached one or more affinity ligand or ent active biological molecule such as for example an inhibitor, a cofactor, a prosthetic group, an enzyme, a hormone, an antibody, a nucleic acid.
- affinity ligand or ent active biological molecule such as for example an inhibitor, a cofactor, a prosthetic group, an enzyme, a hormone, an antibody, a nucleic acid.
- Patent application FR 2 605 237 discloses a porous support, for example of silica, on which is fixed by adsorption a polymer derived from polyvinylimidazole which comprises SH functions, and its use for purifying or separating proteins.
- Patent application EP 591 807 discloses a polymer onto which one or more biologically active molecules of the same nature is grafted covalently.
- These molecules can be, for example biotin, digoxin, digitoxigenin or oligonucleotides comprising from 1 to 80 nucleotide units, preferably 15 to 50, and in particular 20 to 35.
- Patent application FR 2019083 discloses a water-soluble polymer-enzyme binary system, used for the enzymatic treatment of substrates, so that after treatment, the products of the enzymatic reaction are separated from the enzyme product- soluble polymer by passage through a semi-permeable membrane.
- the oligonucleotide / organic polymer ligands are obtained by chemical grafting, by covalence, of said oligonucleotides previously synthesized on the reactive organic polymer or made reactive.
- This chemical grafting constitutes a delicate step to be implemented in the sense that it does not make it possible to obtain an optimal orientation of the oligonucleotides and that it can lead to aggregated compounds whose accessibility of the oligonucleotides is limited (Syntheses and Characterization of Conjugates of Nucleic Acid Probes and 6-Aminoglucose-based Polymer ⁇ , Polymers for Advanced Technologies, (1996) volume 8, pp. 297-304).
- the present invention therefore relates to a complex chemical compound capable of simplifying and improving the production of ligands according to the prior art, while preserving them.
- the first object of the invention is a complex chemical compound comprising:
- - at least one conjugate comprising: - a reactive organic polymer, the backbone of which comprises chemical reactive side functions on the one hand with respect to the surface groups of the solid support linked to the latter by covalent bonding, and on the other hand chemical side residues, - a plurality of initiating biomonomers connected to the organic polymer, respectively linked to said chemical residues of said organic polymer, by a covalent bond.
- the above complex chemical compound, or intermediate reagent makes it possible to directly synthesize the biopolymers on the organic polymer, linked in turn by an optionally cleavable bond to a solid support.
- the cleavage of the organic polymer / solid support bond restores in the original state the synthesized biopolymers linked to the organic polymer in the form of ligand.
- the binding of initiator biomonomers to the organic polymer is not cleavable under the conditions of cleavage of the organic polymer / solid support bond.
- ligands can be obtained which can be used for the amplification of detection and capture of target molecules, said ligands being oriented correctly, and having no aggregates.
- these different ligands can have identical or different biopolymers, at least of mixed natures, such as oligonucleotides / peptides.
- solid support means any material in the relatively inert native state capable of being functionalized, to which can be bound a reactive organic polymer as defined below, and which can be used as a support in detection tests, in affinity chromatography and in separation processes.
- Natural, synthetic, chemically modified or non-synthetic materials can be used as solid support, in particular polysaccharides such as cellulose-based materials, for example paper, cellulose derivatives such as cellulose acetate and nitrocellulose , dextran, polymers such as polyvinyl chloride, polyethylene, polystyrene, polyamide, or copolymers based on vinyl and aromatic monomers, esters of unsaturated carboxylic acids, vinylidene chloride, dienes or compounds having nitrile functions (acrylonitrile), vinyl chloride / propylene copolymers, or vinyl chloride / vinyl acetate, copolymers based on glycidyl methacrylate and ethylene dimethyl methacrylate, copolymers based on s
- the complex chemical compound comprises, as a functional solid support, a support of mineral or organic type, more preferably activated silica or functionalized polystyrene.
- the solid support can be without limitation in the form of a microtiter plate, a sheet, a cone, a tube, a well, beads, particles or the like.
- ligand is meant a complex formed of a reactive organic polymer coupled to a plurality of biopolymers, said ligand being for example the complex chemical compound after synthesis of the biopolymers, with or without cleavage of the solid support / organic polymer bond, said ligand being capable of binding to anti-ligands.
- conjugate in the present invention an organic polymer linked to a plurality of initiator biomonomers.
- biopolymers any molecule which can be synthesized in an automatic synthesizer, such as enzymes, hormones, receptors, antigenic determinants, antibodies, DNA, RNA, peptides, glycopeptides, oligosaccharides, and their derivatives and synthetic analogues.
- biomonomers any basic unit, the polymerization of which by the addition of synthons leads to a biopolymer as defined above; in particular biomonomers chemically modified to bind to the organic polymer and play the role of initiating the polymerization of the biopolymer. Mention may be made of amino acids, nucleosides, nucleotides, saccharides, and their derivatives or analogues.
- the initiating biomonomers are of the nucleotide and / or peptide and / or saccharide type. More preferably, the bio onomers are of nucleotide and peptide type.
- reactive organic polymer means any polymer or copolymer, natural or synthetic, with a linear or branched, statistical, alternating, grafted or sequenced, essentially carbon skeleton, carrying once activated substituents allowing covalent reactions to be carried out with solid support and initiating biomonomers.
- the polymer is a copolymer. It carries the biopolymers as lateral substituents linked to the polymer backbone, directly or indirectly, by covalent bonds, thanks to chemical side residues. It carries other lateral substituents present, identical or different from the preceding ones, as lateral substituents linked to the solid support, directly or indirectly, by cleavable covalent bonds, thanks to chemical lateral functions.
- the units of copolymers which are not involved in the establishment of a covalent bond with the initiator biomonomers or the solid support serve in particular to space, in the copolymer, the units carrying the initiator biomonomers, and can thus serve to modulate, in known manner, the properties of the copolymer, for example the properties of solubility.
- the polymer is a polymer carrying reactive functions of the electrophilic and / or thiol and / or disulfide type.
- the polymer is a linear copolymer of maleic anhydride such as poly (maleic anhydride-alt-methyl vinyl ether), (maleic anhydride-alt-ethylene), (maleic anhydride-alt-stryrene) and (maleic anhydride-alt -N-vinylpyrrolidone) and can also be a copolymer of (N-vinylpyrrolidone / N-acryloxysuccinimide).
- the reactive organic polymer or copolymer according to the invention has a molecular mass of between 10,000 and 1,000,000, more preferably between 30,000 and 70,000.
- the copolymer comes for example from the copolymerization of a maleic anhydride monomer and a second suitable monomer, for example methyl vinyl ether, to allow the establishment of a covalent coupling between the copolymer and the solid support on the one hand, and the copolymer and the initiator biomonomers of somewhere else.
- the maleic anhydride monomer carries carbonyl substituents, which can react with a hydroxyl function of the solid support to form a covalent bond of cleavable ester type under predetermined basic conditions, and for others can react with a primary amine function of an initiator biomonomer to form a non-cleavable amide-type covalent bond under the predetermined basic conditions.
- the reactive organic polymer is a linear copolymer of maleic anhydride-alt-methyl vinyl ether.
- the solid support is itself a polymer or a copolymer, it should be understood that it is in this different case of the reactive polymer, in its chemical nature for example.
- reactive organic polymer refers to the fact that the polymer or copolymer carries, before or after activation, reactive chemical substituents, in particular of the electrophilic and / or thiol and / or disulfide type. These substituents can be, for example, the aldehyde, epoxy, haloal yl, ester, carbonyl, isocyanate, isothiocyanate, carbon-activated carbon double bond and maleimide, vinyl sulfone groups.
- lateral function means reactive chemical function, making it possible to carry out any covalent bond, these are for example the electrophilic and / or thiol and / or disulfide radicals cited above, or any other group known to those skilled in the art, and chosen as a function of the desired covalent bond.
- targets or “target molecules” or “anti-ligands” means any molecules capable of being linked to the ligands via biopolymers, in particular nucleic acids such as DNA or RNA or their fragments, simple or double strands, antigens, haptens, peptides, proteins, glycoproteins, hormones, antibodies, oligosaccharides, drugs, their derivatives and synthetic analogues.
- nucleic acids such as DNA or RNA or their fragments, simple or double strands, antigens, haptens, peptides, proteins, glycoproteins, hormones, antibodies, oligosaccharides, drugs, their derivatives and synthetic analogues.
- the ligand / anti-ligand reaction can be carried out directly or indirectly.
- the ligand is specific for the target molecule.
- the ligand is in particular chosen to be capable of forming a ligand / target molecule duplex.
- the duplex can in particular be represented by any couple antigen / antibody, antibody / hapten, chelator / chelated molecule, polynucleotide / polynucleotide, polynucleotide / nucleic acid hybrids, oligosaccharide / oligosaccharide hybrids, hormone / receptor.
- the ligand is capable of forming a duplex with a bi-functional reagent comprising an "anti-ligand" group, responsible for the formation of the duplex with the ligand, and in which said anti-ligand group is linked , in particular by covalence, in a known manner, to a partner group of the target.
- the target partner group is a group capable of binding with the target (by forming a target / partner complex) and is therefore capable of capturing the target, under test conditions, by establishing a sufficiently strong bond. to ensure the target-partner interaction, for example by covalence and / or by ionic interactions and / or by hydrogen bonds and / or by hydrophilic hydrophobic bonds.
- the ligand / anti-ligand duplex can in this case be any couple mentioned above for the direct type reaction, or else a biotin / streptavidin, lectin / sugar or the like duplex.
- the ligand / anti-ligand complex is a polynucleotide / polynucleotide hybrid.
- the partner / target complex is of the same type as the ligand / target complex mentioned above for the direct type reaction.
- a second subject of the invention is the process for the chemical synthesis of a complex chemical compound which is the subject of the invention and as described above, comprising a plurality of biomonomers, comprising the following steps: a) a functional support comprising surface groupings; b) at least one reactive organic polymer is available, the backbone of which comprises, on the one hand, chemical side functions complementary to the surface groups of the solid support, and on the other hand chemical side residues, said solid support being inert with respect to -vis of said organic polymer; c) there are biomonomers which initiate biopolymerization, identical or different, comprising on the one hand a reactive substituent and on the other hand a protective group; d) reacting at least one organic polymer:
- the preceding synthesis process is preferably carried out by reacting at least one organic polymer with a plurality of initiator biomonomers, in order to graft these covalently, directly or indirectly, with a plurality of lateral residues of said organic polymer, then reacting the organic polymer linked to the initiating biomonomers with the support solid, to establish at least one covalent bond between a surface group of said solid support and a residue of said organic polymer.
- the process comprises, after step c and before step d, step: c ') the organic polymer is reacted with a reagent generating spacer arms, to grafting onto a plurality of lateral remains of said organic polymer a plurality of spacer arms respectively, each having at their free end a reactive function.
- the spacer arm can be:
- the chemical compound according to the invention is characterized in that the initiating biomonomers are extended and polymerized with synthons each according to a predetermined sequence to obtain biopolymers.
- the chemical compound according to the invention is characterized in that the biopolymers are of oligonucleotide and / or peptide and / or oligonucleotide-peptide type.
- the chemical compound is characterized in that the biopolymers form with the organic polymer ligands capable of binding directly or indirectly to anti-ligands.
- a third object of the invention is the use of the complex chemical compound according to the invention for carrying out the synthesis of biopolymers, comprising the steps of: f) we have identical or different synthons, g) by successive coupling / deprotection cycles, the chains of the biopolymers are grown from the initiator biomonomers respectively, according to at least one and the same predetermined sequence of synthons.
- This synthesis directly on the reactive polymer linked to the solid support makes it possible to obtain a well-defined and correctly oriented biopolymer for detecting and / or capturing target molecules of identical nature.
- the synthesis makes it possible to obtain different biopolymers, such as oligonucleotides and peptides, on the same reactive polymer. It is also possible, by this facilitated synthesis, to obtain in several stages dibiopolymers such as oligonucleotides-peptides, which can for example make it possible to detect in the same sample nucleic and protein materials.
- a fourth object of the invention is the complex chemical compound obtained by the process described previously and its use for different applications, in particular the amplification of capture and / or detection of biological targets, in different bioassay formats (microtiter plate, chromatography, bands, etc.), oligonucleotide sequencing, site-directed mutagenesis , in therapy and other applications adapted to the use of the complex chemical compound according to the invention.
- the reagent obtained can be used to amplify the capture and detection of biological targets.
- synthesis of a complex chemical compound comprising:
- a reactive organic polymer the skeleton of which comprises chemical reactive side functions on the one hand with respect to the surface groups of the solid support linked to the latter by covalent bonding, and on the other hand chemical side residues, - a plurality of mixed initiator biomonomers connected to the organic polymer, linked respectively to said chemical residues of said organic polymer, by a covalent bond, characterized in that the mixed initiator biomonomers are extended and polymerized with other synthons each according to a predetermined sequence of said synthons to obtain mixed biopolymers, such as oligonucleotide and peptide.
- the chemical compound comprises biopolymers of oligonucleotide and peptide or oligonucleotide-peptide type.
- the complex chemical compound comprises biopolymers forming with the organic polymer to which they are linked ligands capable of being linked directly or indirectly to anti-ligands.
- reagents or ligands are obtained, in particular ligands consisting of an organic polymer linked to biopolymers of mixed natures, for example peptides / oligonucleotides, capable of 'be used for amplification of capture and detection of target molecules.
- ligands consisting of an organic polymer linked to biopolymers of mixed natures, for example peptides / oligonucleotides, capable of 'be used for amplification of capture and detection of target molecules.
- These complex polymer / oligonucleotide / peptide compounds can also be used in therapy.
- the oligonucleotide can be an antisense agent and the peptide can be fusogenic, the compound can be used to regulate gene expression and optimize the internalization of the complex in cells.
- S stands for "support” in Figures 1 and 3.
- G stands for
- FIG. 1 represents different possible forms of the complex chemical compound according to the invention, and of the corresponding ligand.
- Figures l (a) and l (a ') represent the complex chemical compound and the corresponding ligand whose biopolymers are oligonucleotides having the same nucleic acid sequence.
- Figures l (b) and l (b ') represent the complex chemical compound and the corresponding ligand, the biopolymers of which are oligonucleotides and peptides.
- Figures l (c) and l (c ') represent the complex chemical compound and the corresponding ligand, the biopolymers of which are oligonucleotides and oligonucleotide-peptides.
- FIG. 2 represents four examples of initiator oligomer.
- the radicals R being for: the monomer I: Dimethoxytrityl, Tertiobutyldimethysilyl, photolabile group, the monomer II: Monomethoxytrityl, Fluorenylmethoxycarbonyl, t-Butoxycarbonyl, photolabile group,
- FIG. 3 represents the general scheme for the synthesis of a complex chemical compound according to Example 1.
- Fluka silica beads (CPG, controlled pore size glass) with a diameter of 2000A, particle size 40-85 ⁇ m and an area of 9.2 m 2 / g are available.
- the glass beads (100-150 ⁇ m) come from the company Polysciences, Inc.
- the H-NMR spectra were recorded on a Bruker AM400 spectrometer operating in a Fourier transformation mode.
- the chemical shifts H were expressed in ppm with reference to the TMS.
- the H signal assignments were made by two-dimensional H-H NMR experiments in a homonuclear relationship.
- the mass analyzes were carried out on a ZAB2-SEQ FAB + spectrometer with a thio-glycerol matrix.
- the polymer used is an alternating copolymer of maleic anhydride and methyl vinyl ether P (AMMVE) supplied by Polysciences, Inc. (Mn 67000g / mol).
- oligodeoxyribonucleotides were synthesized on an ABI 394 instrument (Applied Biosystems, San Francisco, USA) using standard chemistry of DNA ⁇ kind cyanoethyl N, N-diisopropylamino phosphoramidite.
- the beads were suspended in 10 ml of hexaethylene glycol with 6 l of sulfuric acid (more than 95%). The mixture is mixed gently and the reaction is carried out overnight at 90 ° C., then the beads are washed with anhydrous acetone and dried in a desiccator.
- the sequence chosen is a HBV (hepatitis B virus) capture sequence.
- Example 2 The same synthetic principle as in Example 1 is used but using as an organic reactive polymer other anhydride copolymers maleic such as copolymers (maleic anhydride-alt-ethylene), (maleic anhydride-alt-styrene), (maleic anhydride-alt-N-vinylpyrrolidone) or P (AMMVE) of another size (MM10.000 to 1.000 .000).
- maleic such as copolymers (maleic anhydride-alt-ethylene), (maleic anhydride-alt-styrene), (maleic anhydride-alt-N-vinylpyrrolidone) or P (AMMVE) of another size (MM10.000 to 1.000 .000).
- 224 nmol of polymer were dissolved in 1 ml of anhydrous DMSO at 37 ° C.
- 10 mg (13.8 mol) of the nucleotide (I), modified in 3 ′ by an amino arm were dissolved in 1 ml of DMSO.
- Example 2 Same principle of synthesis as in Example 1, using a solid support based on polystyrene. 224 nmol of polymer were dissolved in 1 ml of anhydrous DMSO at 37 ° C. In parallel, 10 mg (13.8 mol) of the nucleotide (I), modified in 3 ′ by an amino arm, were dissolved in 1 ml of DMSO. 20 nmol of copolymer, 2 mol of (I) and 1 mol of dimethylaminopyridine (DMAP- solution at 10 mg / ml in DMSO) are dissolved in a sufficient amount of anhydrous DMSO to reach a final volume of 1 ml.
- DMAP- solution dimethylaminopyridine
- the reaction is stirred at room temperature for 1 hour, then 90 mg of particles based on polystyrene (co-polystyrene resin-1% divinylbenzene, conventionally called Wang resin) functionalized with 4-hydroxymethylphenoxymethyl ends, or 90 mg of polystyrene-co-divinylbenzene (solid support) functionalized with 4-hydroxymethyl-phenylacetamidomethyl ends (PAM resin), or 90 mg of a composite support based on polyacrylamide and an inorganic matrix (Kieselguhr) functionalized by ends 4-hydroxymethyl-phenoxyacetyls (Novabiochem), or 90 mg of a polystyrene support functionalized with polyethylene glycol terminated by a hydroxyl or p-oxybenzyl alcohol function (Novabiochem), or 90 mg of all polystyrene-based resins functionalized by an arm hydroxyl spacer, are added to the solution.
- the reaction is stirred overnight at room temperature.
- the supports are then filtered and was
- Example 5 The polystyrene-based supports are functionalized as described above with P (AMMVE) and the biomonomer (I) and / or the monomer (II) in order to initiate peptide synthesis on solid phase using Fmoc chemistry.
- nucleic acid fragments will be synthesized before the peptides.
- Syntheses of oligonucleotides or peptides are carried out on a spherical support based on porous or non-porous silica, or on polystyrene functionalized with a linear copolymer of maleic anhydride linked to the support by a spacer arm stable in basic medium.
- the objective is not to unhook the conjugate (copolymer / biomolecules) after synthesis.
- These reagents can be used for the capture of biological entity (gene fragments, antigen, antibody) directly from biological media.
- the reaction is stirred at ambient temperature for 1 hour, then 90 mg of CPG 2000A silica beads (Control Pores Glass) or 100 mg of glass (Glass Beads) or 100 mg of polystyrene beads functionalized with an amino spacer are added to the solution.
- the reaction is continued overnight, at room temperature.
- the supports are then filtered and washed meticulously with DMSO, anhydrous acetone and then dried under vacuum in the presence of Calcium Chloride.
- Example 7 Same protocol for the synthesis of spherical supports as in Example 1, or in Example 6, using initiator monomers of oligonucleotide syntheses of type (I), or using initiator monomers of peptide syntheses of type (I) II) or by using initiator monomers of type (III) or (IV), having a photolabile protective group at the site of initiation of the synthesis of the biopolymer.
- the photolabile group used may be, for example, 6-nitroveratryl, 6-nitropiperonyl, methyl-6-nitroveratryl, nitroveratryloxycarbonyl, methyl-6-nitropiperonyl, nitrobenzyl, nitrobenzyloxycarbonyl, dimethyldimethoxybenzyl, dimethylbenzylcarbonyl 7-bromo-nitroindolinyl, hydroxy-methylcinnamoyl, 2-oxymethylene anthraquinone, pirenylmethoxycarbonyl.
- the initiation of the synthesis of the biopolymer will be done by exposure of the support to a range of suitable wavelengths.
- Example 8 Example 8:
- Example 7 Same concept as in Example 7, using flat supports (silicon wafer, micro silica plate) silanized on the surface with an amino silane and then covered with a linear polymer based on maleic anhydride.
- the amino functions of the spacer arm will react with the hydrophilic functions of the polymer to create a stable amide function in basic medium.
- syntheses of oligonucleotides and / or peptides can be initiated in a controlled manner.
- the plates are treated beforehand in an acidic or basic medium or, if a system of specific masks is used, they can be exposed to radiation on delimited areas of their surface, in order to eliminate the photolabile groups.
- the reactive functions thus released, syntheses of biopolymers can be developed on the surface by the conventional methods of chemistry on support.
- These functionalized matrices can be used for gene sequencing or antibody screening.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Structural Engineering (AREA)
- Genetics & Genomics (AREA)
- Polymers & Plastics (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002299555A CA2299555A1 (fr) | 1997-08-07 | 1998-08-03 | Compose chimique complexe, synthese et applications diverses dudit compose |
EP98941531A EP1001996A1 (fr) | 1997-08-07 | 1998-08-03 | Compose chimique complexe, synthese et applications diverses dudit compose |
AU89876/98A AU8987698A (en) | 1997-08-07 | 1998-08-03 | Complex chemical compound, synthesis and various applications of said compound |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9710300A FR2767137A1 (fr) | 1997-08-07 | 1997-08-07 | Compose chimique complexe, synthese et applications diverses dudit compose |
FR97/10300 | 1997-08-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999007749A1 true WO1999007749A1 (fr) | 1999-02-18 |
Family
ID=9510253
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1998/001731 WO1999007749A1 (fr) | 1997-08-07 | 1998-08-03 | Compose chimique complexe, synthese et applications diverses dudit compose |
Country Status (6)
Country | Link |
---|---|
US (1) | US20020055185A1 (fr) |
EP (1) | EP1001996A1 (fr) |
AU (1) | AU8987698A (fr) |
CA (1) | CA2299555A1 (fr) |
FR (1) | FR2767137A1 (fr) |
WO (1) | WO1999007749A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005503474A (ja) * | 2001-09-26 | 2005-02-03 | スミス アンド ネフュー ピーエルシー | 構造により特徴付けられている機能をもつ重合体 |
EP1248679B1 (fr) * | 2000-01-21 | 2005-03-09 | Bio Merieux | Procede d'isolement de proteines ou d'associations de proteines et d'acides nucleiques et complexes de particules et de proteines ainsi formes |
WO2007023181A1 (fr) * | 2005-08-24 | 2007-03-01 | Qiagen Gmbh | Procede de separation de cellules vivantes |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60119318T2 (de) * | 2000-05-29 | 2007-05-03 | Bio Merieux | Biokompatible polymere für die bindung von biologischen liganden |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2019083A1 (fr) * | 1968-09-27 | 1970-06-26 | Monsanto Co | |
GB1290702A (fr) * | 1968-09-27 | 1972-09-27 | ||
US4046723A (en) * | 1976-04-22 | 1977-09-06 | The Dow Chemical Company | Azide bonding of a protein to a latex |
WO1984003053A1 (fr) * | 1983-02-14 | 1984-08-16 | Amf Inc | Supports de polysaccharides modifies |
FR2605237A1 (fr) * | 1986-10-20 | 1988-04-22 | Centre Nat Rech Scient | Support pour la purification et la separation des proteines, procede de preparation et application en chromatographie |
EP0273895A2 (fr) * | 1986-12-24 | 1988-07-06 | Monsanto Company | Synthèse de peptides en phase solide |
EP0561722A1 (fr) * | 1992-03-17 | 1993-09-22 | Bio Merieux | Composés hydrosolubles dérivés d'un homopolymère ou copolymère de l'anhydride maléique, et applications desdits composés au support de molécules biologiques |
EP0591807A2 (fr) * | 1992-10-09 | 1994-04-13 | Bayer Ag | Polymères biologiquement actifs |
EP0632269A1 (fr) * | 1993-06-25 | 1995-01-04 | Bio Merieux | Dispositif pour la capture de molécules cibles, et procédé de capture utilisant ledit dispositif |
-
1997
- 1997-08-07 FR FR9710300A patent/FR2767137A1/fr not_active Withdrawn
-
1998
- 1998-08-03 EP EP98941531A patent/EP1001996A1/fr not_active Withdrawn
- 1998-08-03 CA CA002299555A patent/CA2299555A1/fr not_active Abandoned
- 1998-08-03 US US09/485,154 patent/US20020055185A1/en not_active Abandoned
- 1998-08-03 AU AU89876/98A patent/AU8987698A/en not_active Abandoned
- 1998-08-03 WO PCT/FR1998/001731 patent/WO1999007749A1/fr not_active Application Discontinuation
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2019083A1 (fr) * | 1968-09-27 | 1970-06-26 | Monsanto Co | |
GB1290702A (fr) * | 1968-09-27 | 1972-09-27 | ||
US4046723A (en) * | 1976-04-22 | 1977-09-06 | The Dow Chemical Company | Azide bonding of a protein to a latex |
WO1984003053A1 (fr) * | 1983-02-14 | 1984-08-16 | Amf Inc | Supports de polysaccharides modifies |
FR2605237A1 (fr) * | 1986-10-20 | 1988-04-22 | Centre Nat Rech Scient | Support pour la purification et la separation des proteines, procede de preparation et application en chromatographie |
EP0273895A2 (fr) * | 1986-12-24 | 1988-07-06 | Monsanto Company | Synthèse de peptides en phase solide |
EP0561722A1 (fr) * | 1992-03-17 | 1993-09-22 | Bio Merieux | Composés hydrosolubles dérivés d'un homopolymère ou copolymère de l'anhydride maléique, et applications desdits composés au support de molécules biologiques |
EP0591807A2 (fr) * | 1992-10-09 | 1994-04-13 | Bayer Ag | Polymères biologiquement actifs |
EP0632269A1 (fr) * | 1993-06-25 | 1995-01-04 | Bio Merieux | Dispositif pour la capture de molécules cibles, et procédé de capture utilisant ledit dispositif |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1248679B1 (fr) * | 2000-01-21 | 2005-03-09 | Bio Merieux | Procede d'isolement de proteines ou d'associations de proteines et d'acides nucleiques et complexes de particules et de proteines ainsi formes |
JP2005503474A (ja) * | 2001-09-26 | 2005-02-03 | スミス アンド ネフュー ピーエルシー | 構造により特徴付けられている機能をもつ重合体 |
US7955594B2 (en) * | 2001-09-26 | 2011-06-07 | Smith & Nephew, Plc | Polymers with structure-defined functions |
WO2007023181A1 (fr) * | 2005-08-24 | 2007-03-01 | Qiagen Gmbh | Procede de separation de cellules vivantes |
WO2007023057A1 (fr) * | 2005-08-24 | 2007-03-01 | Qiagen Gmbh | Procede pour isoler des acides nucleiques dans le sang |
US8222030B2 (en) | 2005-08-24 | 2012-07-17 | Qiagen Gmbh | Method for the separation of living cells |
US9506107B2 (en) | 2005-08-24 | 2016-11-29 | Qiagen Gmbh | Method for extracting nucleic acid from blood |
Also Published As
Publication number | Publication date |
---|---|
EP1001996A1 (fr) | 2000-05-24 |
FR2767137A1 (fr) | 1999-02-12 |
AU8987698A (en) | 1999-03-01 |
US20020055185A1 (en) | 2002-05-09 |
CA2299555A1 (fr) | 1999-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4923901A (en) | Membranes with bound oligonucleotides and peptides | |
JP3266600B2 (ja) | 固相ペプチド合成のための樹脂を製造する方法 | |
US20030165905A1 (en) | Polymer coated surfaces for microarray applications | |
WO2005097844A1 (fr) | Particule polymere | |
EP1290052B1 (fr) | Polymere biocompatible pour la fixation de ligands biologiques | |
JP2014528014A (ja) | 光反応器およびmipナノ粒子の調製方法 | |
JP2003535317A (ja) | 付加環化バイオコンジュゲーション法を利用してオリゴヌクレオチドを固定化する方法 | |
KR100537400B1 (ko) | 아미노알킬트리알킬실릴 셀룰로오스 및 표면 코팅 방법 | |
WO1999007749A1 (fr) | Compose chimique complexe, synthese et applications diverses dudit compose | |
EP1176423B1 (fr) | Réseaux polymères fixés à des surfaces pour des puces-capteurs | |
FR2887892A1 (fr) | Polymeres fluorescents en solution aqueuse et procede de preparation de polymeres fluorescents solubles en solution aqueuse | |
KR20020013585A (ko) | 다가 어레이 제조 시약 및 방법 및 다가 어레이의 조합라이브러리 | |
US7820785B2 (en) | Solid phase synthesis supports and methods | |
Chaix et al. | Oligonucleotide synthesis on maleic anhydride copolymers covalently bound to silica spherical support and characterization of the obtained conjugates | |
EP1235839A2 (fr) | Produits comprenant un support sur lequel sont fixes des acides nucleiques et leur utilisation comme puce a adn | |
JP4534818B2 (ja) | バイオマテリアル用高分子化合物およびそれを用いた高分子溶液 | |
EP1525210A2 (fr) | Procede de fabrication de puces biologiques | |
Devor et al. | Strategies for attaching oligonucleotides to solid supports | |
JP3148029B2 (ja) | 多糖誘導体モノマーの製造法 | |
WO2002046759A1 (fr) | Dispositif de capture d'une molecule cible | |
JP2010275403A (ja) | 分子インプリントポリマー | |
JP2003261590A (ja) | 新規なデンドリマー及びそれを用いたクラスター誘導体の合成法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2299555 Country of ref document: CA Ref country code: CA Ref document number: 2299555 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09485154 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998941531 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1999511757 Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1998941531 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998941531 Country of ref document: EP |